TKL Research Opens New Primary Research Clinic

FAIR LAWN, N.J.--TKL Research, a full-service clinical research organization (CRO), has officially opened its doors to its new primary research clinic in Fair Lawn, NJ. This enhanced 25,000 square foot facility, located 20 miles northwest of Manhattan, boasts a 70% increase in space over TKL's prior clinic. The increase in size has made it possible to create a sophisticated 30-bed Phase I pharmacology unit and multiple examination rooms for outpatient studies.

The grand opening of this clinic marks a strategic move to further capitalize on the TKL's strengths as well as unmet needs within the industry. "The Fair Lawn research facility will enable us to meet the increased demand for our services in the diseased-state populations for Phase I clinical trials in which we have strong patient recruitment expertise, " said TKL Research President and CEO Jon C. Anderson, Ph.D.

The expanded capabilities of the Fair Lawn clinic have allowed for many specialized features - two configurable male/female dormitories, a centralized nurses station, two dedicated infusion wards, a comprehensive biopharmaceutical laboratory and a dedicated dermatology research clinic.

Located in the newly constructed Fair Lawn Promenade, accessible directly from New Jersey 208, has been quite advantageous for TKL Research. This central location allows for immediate access to the Northern NJ/NY medical communities, ease in travel for sponsors and subjects as well as broadening TKL's reach when recruiting for various clinical studies.

"This development offered an ideal opportunity for TKL", Anderson said. "We're going to be at the perfect intersection of quality and convenience, all within a short distance to New York City and New Jersey's major thoroughfares."

About TKL Research, Inc.

TKL Research is a full-service, international CRO offering complete Phase 1-4 clinical trial services, often in enrollment-driven therapeutic areas. The company has a solid reputation for reducing clinical trial timelines by taking responsibility for enrollment and site selection. TKL's experience began in dermatology and now includes allergy/respiratory, diabetes, gastroenterology, women's health, and other therapeutic areas.

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.